Heidelberg Pharma AG

Regulatory Filings • Oct 12, 2007

News Details

Ad-hoc | 12 October 2007 09:45

WILEX´ second product enters Phase III trial: IND approval from FDA for registration trial with CA9-SCAN

WILEX AG / Miscellaneous

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

WILEX´ second product enters Phase III trial: IND approval from FDA for
registration trial with CA9-SCAN

Munich, 12 October 2007 – The Munich-based biopharmaceutical company WILEX
AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) has
received an Investigational New Drug (IND) approval from the U.S. Food and
Drug Administration (FDA) for a pivotal Phase III trial with the medical
product candidate CA9-SCAN.

190 patients suspected of having kidney cancer will be enrolled in
approximately 17 study centres in the USA. Patients with a renal mass are
scheduled for surgery to remove the affected kidney. These patients will be
imaged with CA9-SCAN prior to the surgery to determine whether they have
clear cell renal cell cancer. Results are expected to be available at the
end of 2008.
12.10.2007 Financial News transmitted by DGAP

---

Language: English
Issuer: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---